Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

Blood

Volumn 101, Issue 9, 2003, Pages 3391-3397

  Pardanani, Animesh ^b   Reeder, Terra ^b   Porrata, Luis F ^b   Li, Chin Yang ^b   Tazelaar, Henry D ^b   Baxter, E Joanna ^b   Witzig, Thomas E ^b   Cross, Nicholas C P ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMATINIB; INTERLEUKIN 5; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; BREATHING DISORDER; CARDIOGENIC SHOCK; CARDIOTOXICITY; CELL INFILTRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTOGENETICS; DEGRANULATION; DISEASE COURSE; DYSPNEA; EOSINOPHILIA; EXON; FATIGUE; FOLLOW UP; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE FUNCTION; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; LIGAND BINDING; MALE; ORTHOPNEA; PRIORITY JOURNAL; REMISSION; WEIGHT REDUCTION; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; DRUG EVALUATION; ENZYME INHIBITORS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038386031     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3103     Document Type: Article

References (30)

1. Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome. Blood. 1994;84:349-350.
2. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651-1657.
3. Raghavachar A, Fleischer S, Frickhofen N, Heimpel H, Fleischer B. T lymphocyte control of human eosinophilic granulopoiesis: clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol. 1987;139:3753-3758.
4. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535-538.
5. Kitano K, Ichikawa N, Mahbub B, et al. Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies. Br J Haematol. 1996;92:315-317.
6. Bank I, Reshef A, Beniaminov M, Rosenthal E, Rechavi G, Monselise Y. Role of gamma/delta T cells in a patient with CD4+CD3- lymphocytosis, hypereosinophilia, and high levels of IgE. J Allergy Clin Immunol. 1998;102:621-630.
7. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med. 2001;3:9.
8. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
9. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
10. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
11. Keene P, Mendelow B, Pinto MR, et al. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. Br J Haematol. 1987;67:25-31.
12. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
13. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84-87.
14. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood. 2000;95:1788-1796.
15. Popovici C, Zhang B, Gregoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood. 1999;93:1381-1389.
16. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.
17. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol. 1998;58:137-141.
18. Oliver JW, Deol I, Morgan DL, Tonk VS. Chronic eosinophilic leukemia and hypereosinophilic syndromes: proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet. 1998;107:111-117.
19. Weide R, Rieder H, Mehraein Y, et al. Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol. 1997;96:117-123.
20. Bain BJ. Hypereosinophilia. Curr Opin Hematol. 2000;7:21-25.
21. Forrest DL, Horsman DE, Jensen CL, et al. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;107:65-68.
22. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
23. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
24. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
25. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
26. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344;1031-1037.
27. Abe A, Tanimoto M, Towatari M, et al. Acute myeloblastic leukemia (M2) with translocation (7;11) followed by marked eosinophilia and additional abnormalities of chromosome 5. Cancer Genet Cytogenet. 1995;83:37-41.
28. Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA. Human peripheral blbod eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med. 1997;186:313-323.
29. Hartman M, Piliponsky AM, Temkin V, Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood. 2001;97:1086-1091.
30. Oliveira SH, Taub DD, Nagel J, et al. Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis. Blood. 2002;100:4291-4297.